Curated News
By: NewsRamp Editorial Staff
September 18, 2026

Onco-Innovations Advances ONC010 Toward First-in-Human Testing

Discuss on Substack
Original Source

TLDR

  • Onco-Innovations advances ONC010 toward first-in-human testing, positioning itself in the competitive DNA repair cancer therapy space.
  • ONC010 combines A83B4C63 with micellar nanoparticles to enhance drug exposure and disrupt DNA repair in cancer cells.
  • Onco-Innovations' ONC010 aims to improve cancer treatment by enhancing radiation and chemotherapy effects, potentially benefiting patients.
  • Onco-Innovations achieved 99.3% purity in a 300-gram batch of A83B4C63, a key step for ONC010's development.

Impact - Why it Matters

Onco-Innovations' progress with ONC010 could lead to a novel cancer therapy that enhances the effectiveness of radiation and chemotherapy by targeting DNA repair mechanisms. If successful, this approach might improve outcomes for patients with solid tumours, addressing a significant unmet need in oncology. The company's focus on scalable manufacturing and regulatory preparedness positions it to potentially enter clinical trials, which is a critical step in bringing new treatments to market. Investors and patients alike should watch for further developments as Onco moves closer to first-in-human studies.

Summary

Onco-Innovations (CBOE CA: ONCO)(OTCQB: ONNVF)(FSE: W1H) is advancing its lead preclinical cancer candidate, ONC010, toward potential first-in-human testing by bringing together drug manufacturing, nanoparticle formulation, analytical development, preclinical studies and regulatory planning. ONC010 combines the company’s PNKP-targeting small molecule A83B4C63 with a micellar nanoparticle delivery system intended to enhance drug exposure and tumor accumulation, with the broader strategy focused on disrupting cancer cells’ DNA repair mechanisms and potentially enhancing the effects of radiation and certain chemotherapy treatments. The company has completed a 300-gram development batch of A83B4C63 at approximately 99.3% purity, advanced polymer manufacturing and identified a non-tin catalyst that could improve impurity control, while also progressing pharmacokinetic, biodistribution, metabolism and ADME studies.

With an Australian subsidiary established, clinical-development partners engaged and new scientific and clinical leadership in place, Onco is now working to integrate these activities into the manufacturing and regulatory package needed for a potential phase I/first-in-human study. To view the full article, visit https://ibn.fm/whdu9.

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Its mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours. For more information, visit the company’s website at https://oncoinnovations.com/. The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF. This content is disseminated by InvestorWire, a specialized communications platform with a focus on advanced wire-grade press release syndication, part of the Dynamic Brand Portfolio @ IBN.

Source Statement

This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Onco-Innovations Advances ONC010 Toward First-in-Human Testing

Blockchain registration record for this content